Skip to main content
Erschienen in: Journal of Cancer Survivorship 4/2020

11.03.2020 | Review

Quality of life in “chronic” cancer survivors: a meta-analysis

verfasst von: Jenny Firkins, Lissi Hansen, Martha Driessnack, Nathan Dieckmann

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer survivors are now living longer giving rise to a new concept—chronic cancer as survivors continue to face long-term consequences of cancer and its treatment. For these survivors, QOL becomes a vital consideration in understanding their survivorship and the long-term impact of cancer and its treatment. The primary aim of this review is to describe QOL in cancer survivors two or more years from diagnosis.

Methods

A meta-analysis was completed of relevant studies assessing QOL in long-term cancer survivorship using PubMed, CINHAL, and PsycINFO. A total of 64 articles met inclusion criteria and included in the analysis. Standardized effect sizes and errors were calculated using previously published standard QOL pass rates to compare QOL across measurement tools and calculate cumulative effect sizes (CES). Fixed-effect or random-effects models were used based on the presence of significant heterogeneity of ≤ 0.10.

Results

Physical health (CES = − 0.894; CI, − 1.472, − 0.316), role-physical health (CES = − 2.039; CI, − 2.643, − 1.435), and mental health (CES = − 0.870; CI, − 1.447, − 0.292) had large, negative cumulative effect sizes signifying worse QOL compared with acceptable QOL rates. Tested moderators, cancer type, average age, country of origin, time since diagnosis, or decade of diagnosis, were not significant to explain heterogeneity between included studies.

Conclusion

QOL is significantly impacted 2 to 26 years after cancer diagnosis. More research is needed to determine possible moderators of QOL in long-term cancer survivors.

Implications for Cancer Survivors

QOL continues to be significantly impacted in long-term cancer survivorship. More research is needed to understand the impact of these findings on care needs for survivors with chronic cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Berlinger N, Flamm AL. Define ‘effective’: the curious case of chronic cancer. Hast Cent Rep. 2009;39(6):17–20.CrossRef Berlinger N, Flamm AL. Define ‘effective’: the curious case of chronic cancer. Hast Cent Rep. 2009;39(6):17–20.CrossRef
8.
Zurück zum Zitat Noone AMHN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al., editors. SEER cancer statistic review, 1975–2015. Bethesda, MD: National Cancer Institute; 2018. Noone AMHN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al., editors. SEER cancer statistic review, 1975–2015. Bethesda, MD: National Cancer Institute; 2018.
10.
18.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Clin Res. 2009;339:b2700. https://doi.org/10.1136/bmj.b2700.CrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Clin Res. 2009;339:b2700. https://​doi.​org/​10.​1136/​bmj.​b2700.CrossRef
20.
Zurück zum Zitat Heydarnejad MS, Hassanpour DA, Solati DK. Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci. 2011;11(2):266–70.PubMedPubMedCentral Heydarnejad MS, Hassanpour DA, Solati DK. Factors affecting quality of life in cancer patients undergoing chemotherapy. Afr Health Sci. 2011;11(2):266–70.PubMedPubMedCentral
22.
Zurück zum Zitat Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute New England Medical Center; 1993. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute New England Medical Center; 1993.
23.
Zurück zum Zitat Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30 reference values. Brussels, Belgium: EORTC Quality of Life Group; 2008. Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30 reference values. Brussels, Belgium: EORTC Quality of Life Group; 2008.
24.
Zurück zum Zitat Higgins JP, Green SE (2011) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Higgins JP, Green SE (2011) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration.
26.
47.
Zurück zum Zitat Holzner B, Kemmler G, Kopp M, Moschen R, Schweigkofler H, Dunser M, et al. Quality of life in breast cancer patients--not enough attention for long-term survivors? Psychosomatics. 2001;42(2):117–23.CrossRef Holzner B, Kemmler G, Kopp M, Moschen R, Schweigkofler H, Dunser M, et al. Quality of life in breast cancer patients--not enough attention for long-term survivors? Psychosomatics. 2001;42(2):117–23.CrossRef
51.
Zurück zum Zitat Kendall AR, Mahue-Giangreco M, Carpenter CL, Ganz PA, Bernstein L. Influence of exercise activity on quality of life in long-term breast cancer survivors. Qual Life Res. 2005;14(2):361–71.CrossRef Kendall AR, Mahue-Giangreco M, Carpenter CL, Ganz PA, Bernstein L. Influence of exercise activity on quality of life in long-term breast cancer survivors. Qual Life Res. 2005;14(2):361–71.CrossRef
78.
Zurück zum Zitat Rogers SN, Hannah L, Lowe D, Magennis P. Quality of life 5-10 years after primary surgery for oral and oro-pharyngeal cancer. J Craniomaxillofacial Surg. 1999;27(3):187–91.CrossRef Rogers SN, Hannah L, Lowe D, Magennis P. Quality of life 5-10 years after primary surgery for oral and oro-pharyngeal cancer. J Craniomaxillofacial Surg. 1999;27(3):187–91.CrossRef
91.
Zurück zum Zitat Cummings A, Grimmett C, Calman L, Patel M, Permyakova NV, Winter J, et al. Comorbidities are associated with poorer quality of life and functioning and worse symptoms in the 5 years following colorectal cancer surgery: results from the ColoREctal Well-being (CREW) cohort study. Psycho-oncology. 2018;27(10):2427–35. https://doi.org/10.1002/pon.4845.CrossRefPubMedPubMedCentral Cummings A, Grimmett C, Calman L, Patel M, Permyakova NV, Winter J, et al. Comorbidities are associated with poorer quality of life and functioning and worse symptoms in the 5 years following colorectal cancer surgery: results from the ColoREctal Well-being (CREW) cohort study. Psycho-oncology. 2018;27(10):2427–35. https://​doi.​org/​10.​1002/​pon.​4845.CrossRefPubMedPubMedCentral
Metadaten
Titel
Quality of life in “chronic” cancer survivors: a meta-analysis
verfasst von
Jenny Firkins
Lissi Hansen
Martha Driessnack
Nathan Dieckmann
Publikationsdatum
11.03.2020
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 4/2020
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-020-00869-9

Weitere Artikel der Ausgabe 4/2020

Journal of Cancer Survivorship 4/2020 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.